RxDoctor Payments Data

Ashish Verma, MD

Internal Medicine · Sturgis, MINPI 1699735936

Payments from drug & device makers

$2,301in general payments, 2019–2025

Across 34 payments — averaging $67.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Inari Medical, Inc.$523
  • Antares Pharma, Inc.$189
  • Novo Nordisk$85
  • Astellas Pharma US Inc$65
  • Clarus Therapeutics Inc.$54
  • plus $73 from 4 others

What the payments were for

  • Travel & lodging$1,18652%
  • Food & beverage$1,11448%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,301 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$106,799
Medicare patients
354
Services billed
1,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$131,333
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$122,970
XareltoRivaroxaban74$74,533
JanuviaSitagliptin Phosphate39$56,877
JardianceEmpagliflozin40$55,367
OzempicSemaglutide28$39,400
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$31,525
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$19,993
Lantus SolostarInsulin Glargine,hum.Rec.Anlog103$18,386
Novolog FlexpenInsulin Aspart30$14,155
Atorvastatin Calcium594$7,466
Albuterol Sulfate HfaAlbuterol Sulfate102$6,406
MesalamineMesalamine W/Cleansing Wipes12$5,756
SymbicortBudesonide/Formoterol Fumarate18$5,480
Ibandronate Sodium90$5,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$39,40028 claims
AstraZenecaSymbicort$13$5,48018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Sturgis

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →